Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin T King

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Cancer|July 6, 2018
Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancerMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patientsJoseph A Miccio, Wesley J Talcott, Vikram Jairam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerBen Y Durkee, Yushen Qian, Erqi L Pollom, et al.
Brachytherapy|March 25, 2016
Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapyMartin T King, Nicola J Nasser, Nitin Mathur, et al.
Brachytherapy|August 22, 2025
Intraoperative low-dose rate brachytherapy as an adjunct to surgery for marginally resectable rectal and recurrent anorectal carcinomasMustafa M Al Balushi, Teresia M Perkins, Kee-Young Shin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2025
Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapyJenna Adleman, Pierre-Yves McLaughlin, James M G Tsui, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 3, 2017
Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lungMichael S Binkley, Martin T King, Joseph B Shrager, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Cancer|July 6, 2018
Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancerMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patientsJoseph A Miccio, Wesley J Talcott, Vikram Jairam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerBen Y Durkee, Yushen Qian, Erqi L Pollom, et al.
Brachytherapy|March 25, 2016
Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapyMartin T King, Nicola J Nasser, Nitin Mathur, et al.
Brachytherapy|August 22, 2025
Intraoperative low-dose rate brachytherapy as an adjunct to surgery for marginally resectable rectal and recurrent anorectal carcinomasMustafa M Al Balushi, Teresia M Perkins, Kee-Young Shin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2025
Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapyJenna Adleman, Pierre-Yves McLaughlin, James M G Tsui, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 3, 2017
Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lungMichael S Binkley, Martin T King, Joseph B Shrager, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Pageof 7